• A mouse study suggests inhaled CBD may reduce inflammatory activity in the brain linked to Alzheimer’s disease.
  • Researchers found changes in immune pathways and pro-inflammatory molecules after CBD treatment.
  • The findings are promising, but this is animal research and does not prove CBD treats Alzheimer’s in people.

CBD is being studied for a range of possible effects, including on brain inflammation.

A new mouse study suggests it may influence inflammatory pathways involved in Alzheimer’s disease.

Alzheimer’s research has traditionally focused on amyloid plaques and tau tangles.

Those are still central features of the disease.

But chronic inflammation in the brain is increasingly seen as another important driver of damage.

 

In this study, researchers used a mouse model of Alzheimer’s disease and delivered CBD through inhalation.

They then examined immune activity and inflammatory signalling in the brain and spinal cord.

CBD reduced the activity of several regulators linked to neuroinflammation.

It was also associated with lower levels of pro-inflammatory molecules.

That suggests CBD may calm some of the immune overactivation seen in Alzheimer’s models.

The researchers say this could matter because Alzheimer’s is not driven by one pathway alone.

A treatment that affects several processes at once may eventually be more useful than one focused on a single target.

That is the optimistic view.

But the evidence still needs to be kept firmly in context.

This was not a human trial.

It does not show that CBD slows Alzheimer’s in patients, improves memory or prevents dementia.

It also does not mean over-the-counter CBD products should be treated as medicine.

The study is useful because it adds to the biological case for targeting brain inflammation.

CBD may be one way to explore that pathway, but there is a long distance between promising mouse data and a safe, effective treatment for people.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.